Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P. Lintermans A, et al. Among authors: van asten k. Breast Cancer Res Treat. 2014 Jul;146(1):109-16. doi: 10.1007/s10549-014-2986-7. Epub 2014 May 11. Breast Cancer Res Treat. 2014. PMID: 24816806
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A, Vanderschueren D, Verhaeghe J, Van Asten K, Jans I, Van Herck E, Laenen A, Paridaens R, Billen J, Pauwels S, Vermeersch P, Wildiers H, Christiaens MR, Neven P. Lintermans A, et al. Among authors: van asten k. Eur J Cancer. 2014 Nov;50(17):2925-31. doi: 10.1016/j.ejca.2014.08.012. Epub 2014 Oct 7. Eur J Cancer. 2014. PMID: 25304297
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.
Lambertini M, Pinto AC, Ameye L, Jongen L, Del Mastro L, Puglisi F, Poggio F, Bonotto M, Floris G, Van Asten K, Wildiers H, Neven P, de Azambuja E, Paesmans M, Azim HA Jr. Lambertini M, et al. Among authors: van asten k. Br J Cancer. 2016 Dec 6;115(12):1471-1478. doi: 10.1038/bjc.2016.359. Epub 2016 Nov 1. Br J Cancer. 2016. PMID: 27802449 Free PMC article.
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.
Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné AS, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé VO, Van Calster B, Guchelaar HJ. Neven P, et al. Among authors: van asten k. Clin Cancer Res. 2018 May 15;24(10):2312-2318. doi: 10.1158/1078-0432.CCR-17-3028. Epub 2018 Feb 19. Clin Cancer Res. 2018. PMID: 29459457 Clinical Trial.
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H, Floris G, Van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan MM, Viale G, Thürlimann B, Vergote I, Christodoulou E, Van Calster B, Neven P. Van Asten K, et al. Oncologist. 2019 Feb;24(2):165-171. doi: 10.1634/theoncologist.2018-0176. Epub 2018 Aug 31. Oncologist. 2019. PMID: 30171067 Free PMC article.
Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.
Brouckaert O, Van Asten K, Laenen A, Soubry A, Smeets A, Nevelstreen I, Vergote I, Wildiers H, Paridaens R, Van Limbergen E, Weltens C, Moerman P, Floris G, Neven P; Multidisciplinary breast centre Leuven. Brouckaert O, et al. Among authors: van asten k. Breast Cancer Res Treat. 2018 Feb;168(1):189-196. doi: 10.1007/s10549-017-4579-8. Epub 2017 Nov 20. Breast Cancer Res Treat. 2018. PMID: 29159760
13 results